Replimune Group (NASDAQ:REPL) Price Target Raised to $22.00

Replimune Group (NASDAQ:REPL) had its price objective lifted by HC Wainwright from $21.00 to $22.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has a buy rating on the stock.

REPL has been the subject of several other reports. Jefferies Financial Group raised their target price on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th. BMO Capital Markets lifted their price objective on Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $19.29.

Replimune Group Stock Performance

Replimune Group stock opened at $14.10 on Thursday. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18. The firm has a market cap of $964.72 million, a P/E ratio of -4.62 and a beta of 1.30. Replimune Group has a 1-year low of $4.92 and a 1-year high of $17.00. The firm has a 50-day moving average of $12.54 and a 200-day moving average of $11.73.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). Sell-side analysts expect that Replimune Group will post -2.88 EPS for the current year.

Insider Transactions at Replimune Group

In related news, CEO Sushil Patel sold 10,000 shares of the company’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the transaction, the chief executive officer now owns 202,014 shares in the company, valued at $2,509,013.88. The trade was a 4.72 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the sale, the insider now directly owns 109,885 shares in the company, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in REPL. Braidwell LP lifted its position in Replimune Group by 203.0% in the 3rd quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock valued at $33,656,000 after acquiring an additional 2,057,460 shares in the last quarter. Boxer Capital Management LLC bought a new position in shares of Replimune Group during the fourth quarter valued at $21,754,000. State Street Corp boosted its position in shares of Replimune Group by 102.1% during the third quarter. State Street Corp now owns 2,340,042 shares of the company’s stock valued at $25,647,000 after buying an additional 1,182,181 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Replimune Group by 11.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company’s stock worth $132,761,000 after buying an additional 1,083,633 shares in the last quarter. Finally, Baker BROS. Advisors LP raised its position in Replimune Group by 10.0% in the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock worth $121,057,000 after buying an additional 1,000,000 shares during the last quarter. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.